Infinity Capital Investments S.A. (BVB: INFINITY) Stock Analysis & Fundamentals

INFINITYInfinity Capital Investments S.A.

BVB · RO · Financial Services · Asset Management · infinitycapital.ro

4.710RON+2.39%Mkt Cap: 368.39M $P/E: 13.08Today

Infinity Capital Investments S.A. is a private equity and venture capital firm specializing in investments in asset management, expansion, development, start-up, growth capital, turnaround, and restructuring. The firm al…

Headline	Source	Time
Older
Bursă. Fondul de investiţii Infinity a încheiat prima jumătate din an cu un profit net consolidat în cre	Ziarul Financiar	Aug 14
Infinity Capital a raportat un profit de 93,2 milioane lei, în primele șase luni	FFinancial Intelligence	Aug 14
Bursă. Infinity Capital a vândut din Antibiotice, Lion Capital şi Banca Transilvania în primul trimestru	Ziarul Financiar	May 19
Bursă. Infinity Capital a vândut din Antibiotice, Lion Capital şi Banca Transilvania...	Ziarul Financiar	May 19
Bursă. Infinity Capital anunţă pierderi de 1,8 mil. lei şi un activ net de 4,6 mld. lei la final de marti	Ziarul Financiar	May 18
Infinity Capital Investments promovează ofertă de răscumpărare pentru aproape 10% din acțiunile proprii. Societatea a obținut un rezultat net de 1 miliard de lei în 2025	Profit.ro	Mar 4
Infinity Capital Investments și Gravity Capital Investments devin acționari ai PAID România	RRevista Biz	Sep 16
Heineken’s Strongbow adds NaviLens levels to packaging The cider brand has added a high-contrast NaviLens QR code to its cans.	Packaging Gateway	Sep 9
3 firms to lay off hundreds of North Jersey-based employees BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty	The Bergen Record	Sep 9
Novartis to acquire Tourmaline Bio for $1.4 billion Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.	Reuters	Sep 9
Novartis to acquire Tourmaline Bio for $1.4 billion Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.	Reuters	Sep 9
Infinity Capital Investments şi-a răscumpărat 9,8% din capital	Ziarul Bursa	Aug 22

Industry Peers